ABSTRACT
Tinospora cordifolia is one of the indispensable medicinal plants used in veterinary folk medicine/Ayurvedic system of medicine for the treatment of diverse diseases and recommended for improving the immune system by means of body resistance. In the current study, we evaluated the genotoxic risk of the aqueous extract of T. cordifolia (TC) in a battery of four different genotoxicity tests viz., Ames, in vitro chromosome aberration (CA), rodent bone marrow micronucleus (MN), and Comet assay. Experimental results confirmed that in Ames test up to 5000 microg/plate of TC did not exhibit any mutagenic effect in Salmonella typhimurium mutant strains (TA97a, TA98, TA100, TA102, and TA1535). In CA assay, TC was not clastogenic to human peripheral blood lymphocytes up to a concentration of 3000 microg/ml. In MN and Comet assays, TC was pre-treated for 7 days at three dose levels (150, 200 and 250 mg/kg body weight) orally to male Balb/c mice. The results showed that TC treatment did not display clastogenicity and DNA damaging effect in bone marrow erythrocytes and peripheral blood lymphocytes respectively.
Subject(s)
Mutagens/toxicity , Plant Extracts/toxicity , Tinospora/toxicity , Animals , Bone Marrow/drug effects , Chromosome Aberrations/chemically induced , DNA Damage , Humans , Lymphocytes/drug effects , Male , Mice , Mice, Inbred BALB C , Mutagenicity Tests/methods , Salmonella typhimurium/drug effectsABSTRACT
1. The pharmacokinetics of sparfloxacin in broiler chicken was investigated following a single intravenous dose of 10 mg/kg and a single oral dose of 20 mg/kg. The pharmacokinetic parameters (AUC(0-24) or C(max)) were integrated with the pharmacodynamic parameter (MIC(90)) to optimize sparfloxacin dosage in chicken. 2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively. Oral bioavailability was 61.7%. 3. Sparfloxacin was found to possess clinically useful pharmacokinetic properties. Based on pharmacokinetic/pharmacodynamic integration an oral dose of 20 mg/kg sparfloxacin for every 24 h might be recommended for a successful clinical effect in chickens.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Chickens/metabolism , Fluoroquinolones/pharmacokinetics , Animals , Anti-Bacterial Agents/administration & dosage , Area Under Curve , Dose-Response Relationship, Drug , Fluoroquinolones/administration & dosage , Fluoroquinolones/blood , Half-LifeABSTRACT
Pharmacokinetics of ofloxacin, a fluoroquinolone antimicrobial agent, was determined in broiler chickens after intravenous or oral administration of a single dose (10 mg/kg). Ofloxacin concentrations in plasma were determined using a high-performance liquid chromatography assay. Plasma concentration profiles were analyzed by the noncompartmental method. Elimination half-life and mean residence time of ofloxacin in plasma were 4.46 and 5.48 h after intravenous administration and 5.85 and 7.43 h, respectively, after oral administration. Maximal plasma concentration of 3.65 microg/mL was achieved at 1.25 h after oral administration. Apparent volume of distribution of 1.76 and 2.16 L/kg and total body clearance of 4.96 and 4.5 mL/min/kg were obtained following intravenous and oral administration, respectively. The oral bioavailability of ofloxacin was 110.01%. Ofloxacin was found to be more rapidly absorbed, widely distributed and more quickly eliminated than other fluoroquinolones in broilers. Based on these kinetic parameters, a dosage of 10 mg/kg given orally every 24 h can be recommended for the treatment of bacterial infections with MIC90 < 0.3 microg/mL.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Chickens/metabolism , Ofloxacin/pharmacokinetics , Administration, Oral , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Area Under Curve , Chromatography, High Pressure Liquid , Infusions, Intravenous/veterinary , Ofloxacin/administration & dosage , Ofloxacin/blood , Poultry ProductsABSTRACT
This study was conducted to investigate the effect of Omega-3 PUFA on streptozotocin (STZ)-induced diabetic cardiomyopathy in wistar rats. After 4 weeks of STZ (60 mg/kg, i.v.) administration, the diabetic animals were randomly divided into two groups: Diabetic control and Omega-3 PUFA treated diabetic rats. Omega-3 PUFA (0.5 ml/kg) was administered to the latter group for 10 weeks. Age matched normal rats served as Normal controls. During the study, plasma glucose, glycosylated hemoglobin, plasma cholesterol, LDL and HDL cholesterol, triglyerides were evaluated in all the groups. Omega-3 PUFA treatment did not normalise but instead blunted the effect of diabetes with regards to the above parameters significantly (P<0.01). At the end of the experiment, morphometric and histochemical studies were performed on heart and myocardial enzyme markers were studied. In the diabetic control group, diabetic cardiomyopathy was characerised by elevated CPK (DC 110+/-8.85 vs. NC 39+/-5.83) and morphological changes in heart. Gravimetric ratios showed increased heart-to-body weight ratio in diabetic control over normal control group. (DC 3.38+/-0.05 vs. NC 2.48+/-0.03). Histochemical evidence showed increased accumulation of PAS-positive material in myocardial interstitium (++++). The Omega-3 PUFA treatment blunted all these adverse effects of diabetes on heart significantly (P<0.001). However, further studies are warranted to elucidate the mechanism by which Omega-3 PUFA decreases the accumulation of PAS-positive material in diabetic myocardium.
